PROMIS偏好评分系统(PROPr)在接受血液透析或肾移植患者中的评估
该研究对524例接受肾脏替代治疗(血液透析或肾移植)的成人进行横断面二次分析,评估PROPr的结构效度。PROPr与SF-6D(r=0.79)和EQ-5D-5L(r=0.71)呈强相关,且能区分不同健康状况,支持其在该人群中的有效性。
要点
- PROPr与SF-6D和EQ-5D-5L均呈强相关,结构效度良好。
- PROPr能区分透析与肾移植、抑郁症状等健康状况。
- PROPr可用于肾脏替代治疗患者的健康效用评估。
核心结论
- PROPr在接受肾脏替代治疗的患者中具有结构效度。
研究设计与样本
- 多中心横断面研究的二次分析,纳入2016年4月至2020年3月在加拿大多伦多招募的524例接受血液透析或肾移植的成人。
主要发现
- PROPr与SF-6D的相关系数为0.79(95%CI 0.76-0.82),与EQ-5D-5L的相关系数为0.71(95%CI 0.66-0.75)。
- 透析( vs 肾移植)的PROPr估计值为-0.17(95%CI -0.13至-0.21)。
- 肾移植受者eGFR<45 vs ≥45 ml/min per 1.73 m2的PROPr估计值为-0.05(95%CI -0.11至0.01;P=0.08)。
- 中度/重度 vs 无/轻度抑郁症状的PROPr估计值为-0.28(95%CI -0.22至-0.33)。
关键数值与推荐
- PROPr中位评分0.39(IQR 0.24-0.58),SF-6D中位评分0.69(IQR 0.58-0.86),EQ-5D-5L中位评分0.85(IQR 0.70-0.91)。
临床怎么用
- PROPr可基于PROMIS域评分计算,用于肾脏替代治疗患者的健康效用评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: A preference-based health utility score (PROPr) can be calculated using Patient-Reported Outcomes Measurement Information System domain scores. We assessed the construct validity of PROPr among patients treated with KRT (hemodialysis or kidney transplant). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a secondary analysis of data collected in multicenter, cross-sectional studies of adults treated with KRT, recruited between April 2016 to March 2020 in Toronto, Canada. All participants provided informed consent. The outcome was the PROPr score. Coadministered outcome variables included the Short-Form Six-Domain (SF-6D) and EuroQol Five-Domain Five-Level (EQ-5D-5L) scores. Socioeconomic and clinical variables included age, sex, diabetes, eGFR, serum albumin, hemoglobin, KRT, and Charlson Comorbidity Index. Construct validity was assessed through correlations between PROPr and SF-6D or EQ-5D-5L, and associations between PROPr and other exposure variables. Health-condition impact estimates (coefficients for health conditions compared with a referent category, e.g., dialysis versus kidney transplant) were calculated using multivariable linear regression. RESULTS: The mean (SD) age of the 524 participants was 57 (17) years, 58% were male, and 45% were White. Median (interquartile range) score was 0.39 (0.24-0.58) for PROPr, 0.69 (0.58-0.86) for SF-6D, and 0.85 (0.70-0.91) for EQ-5D-5L. Large correlations were observed between PROPr versus SF-6D (0.79; 95% confidence interval [95% CI], 0.76 to 0.82) and EQ-5D-5L (0.71; 95% CI, 0.66 to 0.75). Both PROPr and the other utility indices demonstrated health-condition impact in the expected direction. For example, the estimate for PROPr was -0.17 (95% CI, -0.13 to -0.21) for dialysis (versus kidney transplant), -0.05 (95% CI, -0.11 to 0.01; P=0.08) for kidney transplant recipients with an eGFR of <45 versus ≥45 ml/min per 1.73 m2, and -0.28 (95% CI, -0.22 to -0.33) for moderate/severe versus no/mild depressive symptoms. CONCLUSIONS: Our results support the validity of PROPr among patients treated with KRT.
引用
- Zhang J, Dewitt B, Tang E, et al. Evaluation of PROMIS Preference Scoring System (PROPr) in Patients Undergoing Hemodialysis or Kidney Transplant. Clin J Am Soc Nephrol. 2021. PMID: 34272256. doi:10.2215/CJN.01880221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。